Clinical Trial Update: Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

View source ↗

Summary

Expanded access for bezuclastinib to be coadministered with sunitinib for patients with Gastrointestinal Stromal Tumors has been announced by Cogent Biosciences…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasms
• Gastrointestinal Stromal Tumors

Drugs mentioned

• Bezuclastinib (bezuclastinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors | Status: AVAILABLE